Nonprofit invests in leading specialty prescription and prior authorization solution provider to get Duchenne patients breakthrough medications, faster
BOSTON--(BUSINESS WIRE)--ZappRx, Inc., a digital health company that streamlines specialty medication prescribing, announced today that CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), has invested in the ZappRx platform, in order to add Duchenne to the ZappRx platform in 2019.
Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy that primarily affects boys. The genetic disease causes a progressive loss of muscle strength subsequent to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down. Approximately 15,000 US patients are affected with Duchenne, with a total of 300,000 patients worldwide. While there is currently no cure, there are a growing number of specialty pharmaceuticals emerging from clinical trials which may help significantly with disease management. ZappRx and CureDuchenne’s partnership will drive a more streamlined delivery of these life-changing drugs to Duchenne patients.
“We are delighted to have a partner to help us support a disease where we can have a significant impact. CureDuchenne’s investment and expertise will be instrumental in the strategic development of our neurology-specific platform,” said Zoë Barry, CEO and Founder, ZappRx. “We are proud to collaborate with an incredible organization like CureDuchenne. Together, we will be able to achieve our shared goal of improving the quality of life of patients living with rare diseases like Duchenne.”
“As the healthcare industry evolves and new technologies and therapies are developed, the Duchenne community needs to work with smart, innovative organizations to better treat and cure this devastating disease,” said Debra Miller, founder and CEO of CureDuchenne. “Having seen how ZappRx improved treatment access across Pulmonary conditions, we are looking forward to partnering in our effort toward a similar impact for those with Duchenne.”
To learn more about ZappRx and its revolutionary application for specialty prescribing and prior authorization, please visit them at www.zapprx.com.
To learn more about CureDuchenne and learn how you can help patients suffering from this debilitating disease, please visit them online at www.cureduchenne.org.
ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for specialty prescribing — including pharmacy information, payer/prior authorization requirements, and relevant clinical history. ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls. The platform is currently live in Pulmonary [including Cystic Fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and Idiopathic Pulmonary Fibrosis (IPF)], Cardiology (including Hyperlipidemia and Congestive Heart Failure), and Gastroenterology (including Crohn’s Disease and Ulcerative Colitis). As the company grows, ZappRx plans to expand into other areas, including Rheumatology, Neurology, Oncology, and other rare diseases.
CureDuchenne is the nation’s leading nonprofit organization dedicated to finding a cure for Duchenne, the most common and lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys living today. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. For more information on how to help raise awareness and funds needed for research, please visit www.cureduchenne.org, and follow us on Facebook, Twitter and YouTube.